Dr. Philip Kuriakose, MD
Claim this profileHenry Ford Health System
Studies Hemophilia
Studies Hemophilia A
11 reported clinical trials
20 drugs studied
Affiliated Hospitals
Clinical Trials Philip Kuriakose, MD is currently running
Natural History Study
for Blood Disorders
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this increase in potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. ATHN Transcends is a cohort study to determine the safety, effectiveness, and practice of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. The study consists of 7 cohorts with additional study "arms" and "modules" branching off from the cohorts. The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7)
Recruiting1 award N/A1 criteria
SEVENFACT®
for Hemophilia
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.
Recruiting3 awards Phase 46 criteria
More about Philip Kuriakose, MD
Clinical Trial Related5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Philip Kuriakose, MD has experience with
- Brentuximab Vedotin
- Nivolumab
- Rituximab
- Cyclophosphamide
- Recombinant Von Willebrand Factor
- Tranexamic Acid
Breakdown of trials Philip Kuriakose, MD has run
Hemophilia
Hemophilia A
Hemophilia B
Von Willebrand Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Philip Kuriakose, MD specialize in?
Philip Kuriakose, MD focuses on Hemophilia and Hemophilia A. In particular, much of their work with Hemophilia has involved treating patients, or patients who are undergoing treatment.
Is Philip Kuriakose, MD currently recruiting for clinical trials?
Yes, Philip Kuriakose, MD is currently recruiting for 4 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Philip Kuriakose, MD has studied deeply?
Yes, Philip Kuriakose, MD has studied treatments such as Brentuximab Vedotin, Nivolumab, Rituximab.
What is the best way to schedule an appointment with Philip Kuriakose, MD?
Apply for one of the trials that Philip Kuriakose, MD is conducting.
What is the office address of Philip Kuriakose, MD?
The office of Philip Kuriakose, MD is located at: Henry Ford Health System, Detroit, Michigan 48202 United States. This is the address for their practice at the Henry Ford Health System.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.